alectinib in alk-mutated nsclc
Published 6 years ago • 853 plays • Length 3:59Download video MP4
Download video MP3
Similar videos
-
0:56
nautika1: safety and tolerability of neoadjuvant alectinib in alk-positive nsclc
-
1:42
dr. velcheti on potential of alectinib in frontline alk-positive nsclc
-
6:51
progression in alk nsclc after frontline therapy
-
2:00
updated data from phase 2 study of alectinib in alk–positive non–small–cell lung cancer
-
0:52
dr. stinchcombe on the benefit of alectinib in alk nsclc
-
5:52
ceritinib and alectinib in relapsed alk nsclc
-
1:55
dr. villaflor discusses alectinib in alk nsclc
-
2:50
how do alk-inhibitors work in alk-positive lung cancer?
-
7:13
alectinib for relapsed/refractory alk nsclc
-
0:41
dr. gandhi discusses the role of alectinib in alk lung cancer
-
4:31
alk-positive nsclc: alex trial
-
2:51
highlights on adjuvant alectinib in early alk positive nsclc: the alina study
-
1:07
dr. massarelli on first-line alk nsclc treatment
-
6:04
case study: progression on alk inhibitors in nsclc
-
2:32
dr. shaw discusses ldk378 and alectinib (af802) for alk-positive nsclc
-
6:27
alk inhibitor sequencing in nsclc
-
1:05
what targeted therapies are used for people with the alk mutation?
-
0:58
exploring treatment options for patients with alk-mutated lung cancer
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib